CEO exercised or converted 983 RMD derivative securities | OQRO Insider tradesWhy it stands out
Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
All the details
Dates, kept separate
- Transaction date
- Nov 7, 2025
- Reporting period
- Not applicable
- Filed with the SEC
- Nov 11, 2025
CEOOption exercise
Context
- Classification
option exercise
Code M — exercise or conversion of a derivative security
- Planned / mechanical clue
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
Source receipt
- Record ID
- 0000943819-25-000095
Added to OQROOct 2, 2026, 12:28 PM UTC Data qualityVerified: identifiers matched exactly Reporting personMichael J. Farrell RelationshipDirector, Officer Officer titleChairman and CEO SecurityResMed Common Stock TableNon-derivative (Table I) Transaction dateNov 7, 2025 Acquired / disposedAcquired (A) Shares owned after468,849 Footnotes from the filing
- The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
- Includes 74.3412 shares of ResMed stock purchased on October 31, 2025, through the ResMed Employee Stock Purchase Plan.
Around the same time
Derivative exercise or conversion — not an open-market buy.
CEO sold ~$1.25M of ResMed|
Scheduled in advanceDerivative exercise or conversion — not an open-market buy.